Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SUTENT vs CYRAMZA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor that inhibits platelet-derived growth factor receptors (PDGFR-α and PDGFR-β), vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), stem cell factor receptor (c-KIT), FMS-like tyrosine kinase-3 (FLT3), colony-stimulating factor 1 receptor (CSF-1R), and the glial cell line-derived neurotrophic factor receptor (RET). It inhibits angiogenesis and tumor cell proliferation.
Ramucirumab is a human Ig G1 monoclonal antibody that binds to vascular endothelial growth factor receptor 2 (VEGFR-2) and blocks the interaction between VEGFR-2 and its ligands, VEGF-A, VEGF-C, and VEGF-D, thereby inhibiting receptor activation and subsequent angiogenesis.
Gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate,Advanced renal cell carcinoma (RCC),Adjuvant treatment of adult patients at high risk of recurrent RCC after nephrectomy,Progressive, well-differentiated pancreatic neuroendocrine tumors (p NET) in patients with unresectable locally advanced or metastatic disease
Gastric or gastroesophageal junction adenocarcinoma, as monotherapy or with paclitaxel,Non-small cell lung cancer (NSCLC), in combination with docetaxel,Metastatic colorectal cancer, in combination with FOLFIRI,Hepatocellular carcinoma (HCC), as monotherapy,Off-label: Advanced urothelial carcinoma, endometrial cancer
50 mg orally once daily for 4 weeks, followed by 2 weeks off (schedule 4/2).
8 mg/kg intravenously every 2 weeks or 10 mg/kg intravenously every 2 weeks if used in combination with paclitaxel or FOLFIRI.
Terminal elimination half-life of sunitinib is 40-60 hours; for its primary active metabolite (SU12662) it is 80-110 hours. Steady-state achieved by day 14.
Terminal elimination half-life is approximately 14 days (range 11–17 days) at steady state, supporting a dosing interval of every 2 weeks.
Primarily metabolized by CYP3A4; the major metabolite (N-desethyl sunitinib) is also active and is further metabolized by CYP3A4.
Ramucirumab is a monoclonal antibody; metabolism is via catabolism into small peptides and amino acids (nonspecific proteolytic degradation). No major metabolic enzymes involved.
Renal: 16% of total radioactivity; Fecal: ~70% of total radioactivity (primarily as unchanged parent and metabolites).
Ramucirumab is eliminated primarily via proteolytic catabolism; no renal or biliary excretion occurs. Clearance is 0.014 L/h (0.022 L/h with high VEGF), with a mean terminal half-life of 14 days (range 11–17 days) at steady state.
95% bound to human plasma proteins (albumin and alpha-1-acid glycoprotein).
Approximately 95% bound to serum proteins, primarily albumin and immunoglobulins.
Apparent volume of distribution (Vd/F) is approximately 2230 L (enterprise, not weight-adjusted). The Vd is large, indicating extensive extravascular distribution.
Volume of distribution at steady state is approximately 5.0–6.0 L, corresponding to 0.07–0.09 L/kg (assuming 70 kg body weight), indicating limited extravascular distribution primarily within plasma volume.
Oral bioavailability is approximately 40% (range 30-50%).
Bioavailability is 100% as ramucirumab is administered only by intravenous infusion; no oral or other form is available.
No adjustment for mild-to-moderate renal impairment (Cr Cl ≥30 m L/min); avoid use in severe impairment (Cr Cl <30 m L/min) due to lack of data.
No dose adjustment recommended for mild to moderate renal impairment (Cr Cl >=30 m L/min). Not studied in severe renal impairment or dialysis.
Child-Pugh Class A: 50 mg daily; Class B: reduce to 37.5 mg daily; Class C: not recommended.
No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). For moderate (Child-Pugh B) and severe (Child-Pugh C) hepatic impairment, no dosing information available; use with caution.
Not approved for pediatric use; no established weight-based dosing.
Safety and efficacy not established in pediatric patients.
No specific dose adjustment; monitor renal function and blood pressure more frequently due to increased sensitivity to adverse effects.
No dose adjustment required based on age. Monitor for increased risk of adverse events such as hypertension, hemorrhage, and gastrointestinal perforations.
Hepatotoxicity: Severe, sometimes fatal hepatotoxicity has been observed. Monitor liver function tests before and during treatment. Interrupt or discontinue SUTENT and manage as appropriate.
Hemorrhage: Severe or fatal hemorrhage, including gastrointestinal hemorrhage, hemoptysis, and intracranial hemorrhage, has occurred. Do not administer in patients with severe bleeding.
Hepatotoxicity: Monitor liver function tests before and during therapy; interrupt or discontinue for severe hepatotoxicity.,Cardiovascular events: Hypertension, QT prolongation, left ventricular dysfunction, including heart failure; monitor blood pressure and cardiac function.,Hemorrhage: Severe, sometimes fatal hemorrhagic events; monitor for signs and symptoms.,Thyroid dysfunction: Monitor thyroid function; manage with thyroid hormone replacement as needed.,Adrenal insufficiency: Reported; monitor for symptoms.,Proteinuria: Monitor urine protein; discontinue for nephrotic syndrome.,Wound healing complications: Withhold therapy for at least 24 days prior to elective surgery.,Reversible posterior leukoencephalopathy syndrome (RPLS): Discontinue if signs/symptoms occur.,Thrombotic microangiopathy (TMA): Reported; discontinue if TMA occurs.
Hemorrhage risk: Serious and sometimes fatal hemorrhagic events; permanently discontinue if severe bleeding occurs.,Arterial thromboembolic events: Including myocardial infarction and stroke; discontinue if occurs.,Gastrointestinal perforation: Fatal cases reported; discontinue if occurs.,Impaired wound healing: Interrupt therapy 28 days prior to elective surgery; do not resume until wound fully healed.,Hypertension: Monitor blood pressure; treat with antihypertensives; temporarily withhold if severe hypertension occurs.,Proteinuria: Monitor urine protein; withhold for >2 g/24h; discontinue if nephrotic syndrome develops.,Hypersensitivity/infusion reactions: Permanently discontinue if severe reaction occurs.,Thyroid dysfunction: Monitor thyroid function during treatment.
None known.
Severe hemorrhage (active bleeding),Hypersensitivity to ramucirumab or any excipients
Avoid grapefruit and grapefruit juice during treatment. St. John's wort may reduce efficacy. No other significant interactions.
No specific food interactions are documented. Avoid grapefruit juice if taking concomitant drugs metabolized by CYP3A4 (e.g., simvastatin) due to potential interaction, but no direct interaction with ramucirumab.
Pregnancy category D. First trimester: high risk of embryofetal toxicity including skeletal and cardiovascular malformations. Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and preterm delivery due to antiangiogenic effects. Avoid use in pregnancy.
Cyramza (ramucirumab) is a VEGF receptor antagonist. Based on its mechanism of action and animal studies, it can cause fetal harm when administered to pregnant women. In animal reproduction studies, intravenous administration of ramucirumab to pregnant rabbits during organogenesis resulted in embryofetal mortality and reduced fetal weight at exposures less than the recommended human dose. There are no adequate and well-controlled studies in pregnant women. Cyramza is contraindicated in pregnancy. First trimester: High risk of teratogenicity; VEGF inhibition interferes with embryonic vascular development. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and potential for fetal renal impairment due to anti-angiogenic effects. Avoid use during pregnancy.
No human data available; M/P ratio unknown. Sunitinib and its metabolites are excreted in rat milk. Due to potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated during therapy and for at least 4 weeks after the last dose.
No human data available on the presence of ramucirumab in human milk, effects on the breastfed infant, or effects on milk production. Ramucirumab is a large protein molecule (Ig G1 monoclonal antibody) and is likely to be present in breast milk at low levels, especially in early postpartum period. However, because of the potential for serious adverse reactions in the breastfed infant, advise women not to breastfeed during treatment and for at least 2 months after the last dose. M/P ratio: Not determined.
No pharmacokinetic data in pregnancy; dose adjustments are not established. Given teratogenicity, use is not recommended. If unavoidable, consider reduced dose (e.g., 37.5 mg daily) with close monitoring, but safety and efficacy are not validated.
Cyramza is contraindicated in pregnancy; no dosing adjustments are recommended as use should be avoided. If used inadvertently, no specific pharmacokinetic data in pregnancy are available; however, physiological changes (e.g., increased plasma volume, altered renal function) may affect drug clearance, but no dose adjustment guidelines exist. The risk of fetal harm outweighs any potential benefit, and treatment should be discontinued immediately if pregnancy occurs.
Monitor for hypertension and proteinuria; manage with antihypertensives. Check thyroid function before and during therapy due to risk of hypothyroidism. Monitor liver enzymes and cardiac function, especially in patients with pre-existing conditions. Dose adjustments needed for hepatic impairment (Child-Pugh Class C).
CYRAMZA (ramucirumab) is a VEGFR-2 antagonist; premedicate with antihistamines and acetaminophen before infusion to reduce infusion-related reactions. Monitor blood pressure closely as hypertension is common; hold for severe hypertension. Avoid use in patients with significant bleeding risk or recent thromboembolic events. Do not administer with platinum-based chemotherapy in NSCLC patients with EGFR or ALK mutations unless progression on targeted therapy.
Take with or without food, but avoid grapefruit juice.,Report any signs of bleeding, unusual bruising, or fatigue.,Monitor blood pressure regularly and report high readings.,Watch for changes in skin color (yellowing or darkening) or nail changes.,Use effective contraception during treatment and for at least 4 weeks after stopping.,Avoid sun exposure; use sunscreen and protective clothing.
You may experience high blood pressure; monitor regularly and report symptoms like severe headache or vision changes.,This drug can increase bleeding risk; inform your doctor if you have any unusual bruising or bleeding.,Infusion reactions may occur; you will receive premedication to reduce this risk.,Report any new or worsening shortness of breath, chest pain, or leg swelling as these could be signs of blood clots or heart problems.,Wound healing may be impaired; avoid elective surgery during treatment and inform all healthcare providers you are on this medication.,Effective contraception is required during treatment and for at least 3 months after final dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SUTENT vs CYRAMZA, answered by our medical review team.
SUTENT is a Tyrosine Kinase Inhibitor Antineoplastic that works by Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor that inhibits platelet-derived growth factor receptors (PDGFR-α and PDGFR-β), vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), stem cell factor receptor (c-KIT), FMS-like tyrosine kinase-3 (FLT3), colony-stimulating factor 1 receptor (CSF-1R), and the glial cell line-derived neurotrophic factor receptor (RET). It inhibits angiogenesis and tumor cell proliferation.. CYRAMZA is a Antineoplastic Monoclonal Antibody that works by Ramucirumab is a human Ig G1 monoclonal antibody that binds to vascular endothelial growth factor receptor 2 (VEGFR-2) and blocks the interaction between VEGFR-2 and its ligands, VEGF-A, VEGF-C, and VEGF-D, thereby inhibiting receptor activation and subsequent angiogenesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SUTENT and CYRAMZA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SUTENT is: 50 mg orally once daily for 4 weeks, followed by 2 weeks off (schedule 4/2).. The standard adult dose of CYRAMZA is: 8 mg/kg intravenously every 2 weeks or 10 mg/kg intravenously every 2 weeks if used in combination with paclitaxel or FOLFIRI.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SUTENT and CYRAMZA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SUTENT is classified as Category C. Pregnancy category D. First trimester: high risk of embryofetal toxicity including skeletal and cardiovascular malformations. Second and third trimesters: risk of fetal growth rest. CYRAMZA is classified as Category C. Cyramza (ramucirumab) is a VEGF receptor antagonist. Based on its mechanism of action and animal studies, it can cause fetal harm when administered to pregnant women. In animal rep. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.